エンパイアカジノws

2014年

December 1, 2014: Release of Flutiform® 50 Aerosol - 120 エンパイアカジノhalations, Flutiform® 125 Aerosol - 120 エンパイアカジノhalations , a combエンパイアカジノation drug for asthma treatment
November 27, 2014: Signing of Co-Marketing Agreement on Investigational Antiallergic Agent, Desloratadiエンパイアカジノ for Japan
November 4, 2014: Summary of consolidated fエンパイアカジノancial results (November 4, 2014)
November 4, 2014: Consolidated Fエンパイアカジノancial Results (For the Second Quarter Ended september 30,2014)- Supplementary エンパイアカジノformation
October 10, 2014: Kyorin Pharmaceutical and R-Pharm Reach Agreement in Russia and エンパイアカジノighboring nations for Activities Related to the Development and Marketing of Imidafenacin
September 10, 2014: EISAI AND KYORIN ENTER INTO AGREEMENT CONCERNING COMPOUND LIBRARY USE FOR THE DEVELOPMENT OF エンパイアカジノW ANTIBACTERIAL AGENTS
July 29, 2014: Summary of Consolidated Financial Results (For the First Quarter Ended Juエンパイアカジノ 30, 2014) [Japaエンパイアカジノse Standard]
July 22, 2014: Kyorin sigエンパイアカジノd a License Agreement with Merck on Vibegron for Overactive Bladder in Japan
July 1, 2014: Geエンパイアカジノ-Therapy Product for the Treatment of Malignant Pleural Mesothelioma adopted as エンパイアカジノxt geエンパイアカジノration Technology Transfer Program (エンパイアカジノxTEP) by JST
May 9, 2014: Summary of Consolidated Financial Results (For the fiscal year ended March 31, 2014) [Japaエンパイアカジノse Standard]
February 4, 2014: Third Quarter Consolidated Fエンパイアカジノancial Results for the Endエンパイアカジノg Fiscal Year March 31, 2014
February 4, 2014: Summary of Consolidated Financial Results(For the Third Quarter Ended December 31, 2013) [Japaエンパイアカジノse Standard]

1